Grant4

ORAMED PHARMACEUTICALS INC.

Total Value

$5.7M

Filing Date

Sep 25, 2026

2 transactions

Trade Summary

On Sep 24, 2026, KIDRON NADAV, President and CEO, Director, reported $5.7M of ORAMED PHARMACEUTICALS INC. (ORMP) across 2 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Reported prices ranged from $3.16 to $13.89. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: KIDRON NADAV
Role: President and CEO, Director
Location: NEW YORK, NY

Filing Details

Filing Date: Sep 25, 2026
Transaction Date: Sep 24, 2026
Accession Number: 0001213900-26-103540
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 24, 2026	Common Stock	349,497	—	Grant/Award	—
Sep 24, 2026	Common Stock	368,765	—	Grant/Award	—

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Sep 24, 2026	ORMP derivative	196,500	$3.16	Disposition	$620.9K
Sep 24, 2026	ORMP derivative	190,000	$4.80	Disposition	$912.0K
Sep 24, 2026	ORMP derivative	49,000	$7.77	Disposition	$380.7K
Sep 24, 2026	ORMP derivative	97,000	$8.14	Disposition	$789.6K
Sep 24, 2026	ORMP derivative	150,000	$10.40	Disposition	$1.6M
Sep 24, 2026	ORMP derivative	107,000	$13.89	Disposition	$1.5M

Want live alerts when KIDRON NADAV trades again?

Download Insider Trades to track ORMP, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
(F2)On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
(F3)The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
(F4)The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
(F5)The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested.
(F6)The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
(F7)The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
(F8)The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDRON NADAV

(Last)

(First)

(Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/24/2026		A		349,497	A	⁽¹⁾	3,771,740	D
Common Stock	09/24/2026		A		368,765	A	⁽²⁾	4,140,505	D
Common Stock								126,000	I	By wholly-owned corporation

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$3.16	09/24/2026		D			196,500	⁽³⁾	09/11/2029	Common Stock	196,500	⁽¹⁾	0	D
Stock option (right to buy)	$4.8	09/24/2026		D			190,000	⁽⁴⁾	01/08/2030	Common Stock	190,000	⁽¹⁾	0	D
Stock option (right to buy)	$7.77	09/24/2026		D			49,000	⁽⁵⁾	06/30/2027	Common Stock	49,000	⁽¹⁾	0	D
Stock option (right to buy)	$8.14	09/24/2026		D			97,000	⁽⁶⁾	01/31/2028	Common Stock	97,000	⁽¹⁾	0	D
Stock option (right to buy)	$10.4	09/24/2026		D			150,000	⁽⁷⁾	02/03/2031	Common Stock	150,000	⁽¹⁾	0	D
Stock option (right to buy)	$13.89	09/24/2026		D			107,000	⁽⁸⁾	01/03/2032	Common Stock	107,000	⁽¹⁾	0	D

Explanation of Responses:

1. On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.

2. On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

3. The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

4. The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.

5. The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested.

6. The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.

7. The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

8. The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

	/s/ Nadav Kidron	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001213900-26-103540.

ORAMED PHARMACEUTICALS INC.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when KIDRON NADAV trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4